{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-011838","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.778771+00:00","generated_at":"2026-06-17T03:53:26.442546+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Abeona Therapeutics reduces board size to seven; Chairman moves director class for compliance","bullets":["Board size decreased from nine to seven directors, effective at 2023 Annual Shareholder Meeting.","Chairman Michael Amoroso relinquished Class 2 seat and was appointed Class 1 director to maintain equal class sizes.","Amoroso's service is deemed continuous; no new compensatory arrangements were entered into."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-011838","json":"https://secwatch.observer/filing/0001493152-23-011838.json","markdown":"https://secwatch.observer/filing/0001493152-23-011838.md","text":"https://secwatch.observer/filing/0001493152-23-011838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315223011838/0001493152-23-011838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315223011838/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:53:26.442546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}